CN117693335A - 组合治疗方法 - Google Patents

组合治疗方法 Download PDF

Info

Publication number
CN117693335A
CN117693335A CN202280044354.9A CN202280044354A CN117693335A CN 117693335 A CN117693335 A CN 117693335A CN 202280044354 A CN202280044354 A CN 202280044354A CN 117693335 A CN117693335 A CN 117693335A
Authority
CN
China
Prior art keywords
bupropion
zonisamide
nicotine
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280044354.9A
Other languages
English (en)
Chinese (zh)
Inventor
J·E·罗斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ross Research Center LLC
Original Assignee
Ross Research Center LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ross Research Center LLC filed Critical Ross Research Center LLC
Publication of CN117693335A publication Critical patent/CN117693335A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/32—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by acyclic compounds
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/10—Devices using liquid inhalable precursors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CN202280044354.9A 2021-05-11 2022-05-10 组合治疗方法 Pending CN117693335A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187001P 2021-05-11 2021-05-11
US63/187,001 2021-05-11
PCT/US2022/028504 WO2022240819A1 (en) 2021-05-11 2022-05-10 Combination treatment methods

Publications (1)

Publication Number Publication Date
CN117693335A true CN117693335A (zh) 2024-03-12

Family

ID=84028804

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280044354.9A Pending CN117693335A (zh) 2021-05-11 2022-05-10 组合治疗方法

Country Status (7)

Country Link
US (1) US20250073186A1 (https=)
EP (1) EP4337181A4 (https=)
JP (1) JP2024517335A (https=)
CN (1) CN117693335A (https=)
AU (1) AU2022273620A1 (https=)
CA (1) CA3218448A1 (https=)
WO (1) WO2022240819A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4593814A1 (en) * 2022-09-26 2025-08-06 Rose Research Center, LLC Combination for use in a method of preventing weight gain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518520A (ja) * 1997-10-03 2001-10-16 キャリー メディカル コーポレイション ニコチンレセプターアンタゴニストおよび抗抑うつ薬または抗不安薬を含有するニコチン嗜癖を治療する組成物
US20070212428A1 (en) * 2004-06-04 2007-09-13 Mood Management Sciences, Inc. Methods and compositions for treating mood disorder
US7671094B2 (en) * 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
KR20170077291A (ko) * 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지

Also Published As

Publication number Publication date
JP2024517335A (ja) 2024-04-19
AU2022273620A1 (en) 2023-11-30
US20250073186A1 (en) 2025-03-06
EP4337181A4 (en) 2025-04-16
CA3218448A1 (en) 2022-11-17
EP4337181A1 (en) 2024-03-20
WO2022240819A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
Henningfield et al. Pharmacotherapy for Nicotine Dependence 1
West et al. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler
Schneider et al. The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments
Azzopardi et al. A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products
Schuh et al. Nicotine nasal spray and vapor inhaler: abuse liability assessment
Shiffman et al. Nicotine delivery systems
Rennard et al. Smoking cessation
Caponnetto Well-being and harm reduction, the consolidated reality of electronic cigarettes ten years later from this emerging phenomenon: a narrative review
Cornuz Smoking cessation interventions in clinical practice
Glover et al. A multicenter phase 3 trial of lobeline sulfate for smoking cessation
JP2022548876A (ja) 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物
Schneider et al. Comparative testing of 5 nicotine systems: initial use and preferences
Principe et al. Smoking cessation in the management of Chronic Obstructive Pulmonary Disease (COPD). Narrative review and recommendations
CN117693335A (zh) 组合治疗方法
Schneider et al. Preferences among four combination nicotine treatments
Talwar et al. Pharmacotherapy of tobacco dependence
Rosen et al. Reducing tobacco use in adolescents
Suchanek Hudmon et al. Current approaches to pharmacotherapy for smoking cessation
de Hoyos et al. Perioperative smoking cessation
WO2024073334A1 (en) Combination for use in a method of preventing weight gain
Huber et al. Successful smoking cessation
Shiffman et al. Nicotine delivery systems: How far has technology come?
Robson et al. Tobacco Use Disorders
Jennings et al. Achieving Long‐term Abstinence from Tobacco Use in Patients in a Cardiovascular Prevention and Rehabilitation Setting
Sasiadek et al. Nicotine and Tobacco

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination